Purderal P 100 mg, 400 mg Tablets
PDF Leaflet Revision Date: 7 June 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of tuberculosis in combination with other antituberculosis medicines.
Dosage (summary)
15 mg/kg daily for primary treatment; 25 mg/kg for first 60 days of re-treatment, then 15 mg/kg.
Special Populations
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; breastfeeding not recommended during treatment.
Key Drug Interactions
- Aluminum hydroxide (reduces absorption)
Contraindications
- Hypersensitivity to ethambutol
- Severe renal impairment
- Optic neuritis
Common side effects
- Optic neuritis
- Hyperuricaemia
- Nausea
- Vomiting
- Rash
Counselling Points
- Report any vision changes
- Avoid driving if vision is affected
- Regular ophthalmic examinations recommended for high-risk patients
Serious warnings
- Risk of optic neuritis
- Monitor renal function
Important Disclaimer
The Purderal P 100 mg, 400 mg Tablets professional information leaflet below is the property of Pharmacare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
